Table 1.
Characteristics of eligible studies.
| Authors, year | Study design | Treatment | Patients enrolled | Mean age, years | Male, n (%) | Current/former smokers, n (%) | Stage (n) | Histology (n), Ad/Sq/others | ILD pattern (n), UIP/non-UIP | Lung function (%),median FVC/DLco | Total AE-ILD rate (%) | PS (n) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kenmotsu et al. (13) | Phase II | CB + nab-PTX | 94 | 70 | 89 | IIIA/IIIB/IV/Recurrent (15/23/47/9) | 49/39/6 | 50/44 | 90.1/63.7 | 20.7 | 0/1 (42/52) | |
| Asahina et al. (14) | Phase II | CB + nab-PTX | 36 | 68.5 | 72.2 | 97.2 | IIIB/IV/Recurrent (15/18/3) | 16/15/5 | 12/24 | 96.4/73.1 | 11.1 | 0/1 (13/23) |
| Minegishi et al. (23) | Pilot | CB + weekly PTX | 18 | 71 | 77.8 | 83.3 | IIIA/IIIB/IV or Recurrent (2/3/13) | 6/7/5 | 6/12 | 82/– | 27.8 | 0/1 (7/11) |
| Fukuizumi et al. (15) | Phase II | CB + weekly PTX | 35 | 68 | 88.6 | 94.3 | IIIA/IIIB/IV/Recurrent (15/7/10/3) | 13/16/6 | 18/17 | 89/70 | 18.2 | 0/1 (18/17) |
| Sekine et al. (24) | Pilot | CB + S-1 | 21 | 67 | 90.5 | 95.2 | IIB/IIIIA/IIIB/IV/Recurrent (1/2/10/4/4) | 10/10/1 | 12/9 | 91/63.4 | 38.1 | 0/1/2 (7/12/2) |
| Hanibuchi et al. (16) | Phase II | CB + S-1 | 33 | 70 | 90.9 | 90.9 | IIIB/IV/Recurrent (7/19/7) | 13/16/4 | 22/11 | 0/1 (18/15) | ||
| Yasuda et al. (25) | Retrospective | CB + nab-PTX | 12 | 73 | 91.7 | 100 | IIIA/IIIB/IV (1/4/7) | 7/4/1 | 3/9 | 81.7/90.7 | 8.3 | 0–1/ 2(11/1) |
| Watanabe et al. (26) | Retrospective | CB + weekly PTX CB + DOC NVB | 21 | 68.4 | 85.7 | 100 | IIIB/IV (11/10) | 14/5/2 | 18/3 | 91.6/51.2 | 0/1/2 (8/10/3) | |
| Watanabe et al. (27) | Retrospective | DDP + NVB | 67 | 64 | 95.5 | 100 | IIIB/IV/Recurrent (20/42/5) | 26/21/20 | 0/1/2 (11/53/3) | |||
| Shukuya et al. (28) | Retrospective | CB + weekly PTX | 15 | 68 | 86.7 | IIIA/IIIB/IV/Recurrent (1/5/7/2) | 10/5/0 | 4/11 | 0/1/2 (6/7/2) | |||
| Kinoshita et al. (29) | Retrospective | CB + weekly PTX DDP + NVB DDP + DOC | 22 | 70 | 95.5 | 100 | IIIA/IIIB/IV or Recurrent (1/6/15) | 11/7/4 | 87.2/– | 0/1 (12/10) | ||
| Igawa et al. (30) | Retrospective | CB + nab-PTX | 34 | 71 | 85 | 97 | IIIA/IIIB/IV or Recurrent (2/2/30) | 12/16/6 | 16/18 | 0–1/2–3 (32/2) | ||
| Yamaguchi et al. (31) | Retrospective | DDP + VP-16 | 24 | 63 | 95.8 | IIIA/IIIB/IV (5/6/13) | 12/4/8 | 20/4 | 20.8 | 0/1/2 (14/8/2) | ||
| Kenmotsu et al. (32) | Retrospective | Platinum-based chemotherapy | 104 | 67 | 91.3 | 100 | IIIA or IIIB/IV/Recurrent (41/55/8) | 50/47/7 | 70/34 | 25 | 0–1/2 (96/8) | |
| Shimizu et al. (33) | Retrospective | CB + weekly PTX | 11 | 72 | 91 | 91 | IIIA/IIIB/IV (2/2/7) | 11/0/0 | 3/8 | 0 or 1 | ||
| Araya et al. (34) | Retrospective | CB + nab-PTX | 9 | 69 | 88.9 | 100 | IIIB/IV (2/7) | 1/7/1 | 5/4 | 112.4/55.8 | 22.2 | 0–1/2 (7/2) |
| Niwa et al. (35) | Retrospective | CB + nab-PTX | 9 | 67 | 100 | 100 | IIIA/IIIB/IV (1/1/7) | 0/6/3 | 6/3 | 0/1/2 (0/8/1) | ||
| Fujita et al. (36) | Retrospective | PT + PEM | 24 | 70 | 91.7 | 95.8 | IIIA or IIIB/IV or Recurrent (8/16) | 24/0/0 | 2/22 | 91.2/– | 41.7 | 0–1/2 (22/2) |
| Fujita et al. (37) | Retrospective | CB + nab-PTX | 8 | 77 | 87.5 | 100 | IIIA/IIIB/IV (5/1/2) | 0/8/0 | 4/4 | 81.5/– | 25 | 0/1 (3/5) |
| Kakiuchi et al. (38) | Retrospective | Platinum-based chemotherapy | 35 | 72 | 93.2 | 98.6 | 15/20/0 | |||||
| Choiet al. (39) | Retrospective | CB + GEM CB + PEM | 52 | 67 | 86.5 | 86.5 | I/II/III/IV (2/2/11/37) | 32/13/7 | 13.5 | 0–1/2 (47/5) |
PS, performance status; CB, carboplatin; DDP, cisplatin; PT, platinum; nab-PTX, nano albumin paclitaxel; PTX, paclitaxel; S-1, tegafur-gimeracil-oteracil potassium; DOC, docetaxel; NVB, vinorelbine; VP-16, etoposide; PEM, pemetrexed; GEM, gemcitabine; Sq, squamous; Ad, adenocarcinoma; FVC, forced vital capacity; DLco, diffusing capacity of the lungs for carbon monoxide; UIP, usual interstitial pneumonia.